Research Advances in Kinase Enzymes and Inhibitors for Cardiovascular Disease Treatment

References

• Mozaffarian D, Benjamin EJ, Go AS et al. Heart Disease and Stroke Statistics-2015 Update. A report From the American Heart Association. Circulation 131(4), e29–e322 (2014).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Heart disease facts. www.cdc.gov/heartdisease/facts.htm
   Google Scholar
• Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. Natl Vital Stat. Rep. 64(2), 1–119 (2016).
   PubMedGoogle Scholar
• Kumar R, Singh VP, Baker KM. Kinase inhibitors for cardiovascular disease. J. Mol. Cell Cardiol. 42(1), 1–11 (2007).
   PubMed Web of Science ®Google Scholar
• Vagnozzi RJ, Hoffman NE, Elrod JW, Madesh M, Force T. Protein kinase signaling at the crossroads of myocyte life and death in ischemic heart disease. Drug Discov. Today Ther. Strateg. 9(4), e173–e182 (2012).
   PubMedGoogle Scholar
• Roskoski R Jr. USFDA approved protein kinase inhibitors (2015). www.brimr.org/PKI/PKIs.htm
   Google Scholar
• Kolluru GK, Majumder S, Chatterjee S. Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling. Nitric Oxide 43, 45–54 (2014).
   PubMed Web of Science ®Google Scholar
• Kumar R, Singh VP, Baker KM. Kinase inhibitors for cardiovascular disease. J. Mol. Cell Cardiol. 42(1), 1–11 (2007).
   PubMed Web of Science ®Google Scholar
• Hidalgo CG, Chung CS, Saripalli C et al. The multifunctional Ca2+/calmodulin-dependent protein kinase II delta (CaMKIIδ) phosphorylates cardiac titin’s spring elements. J. Mol. Cell Cardiol. 54, 90–97 (2013).
   PubMed Web of Science ®Google Scholar
• Levy De, Wang DX, Lu Q et al. Aryl–indolyl maleimides as inhibitors of CaMKIIδ. Part 1: SAR of the aryl region. Bioorg. Med. Chem. Lett. 18(7), 2390–2394 (2008).
   PubMed Web of Science ®Google Scholar
• Mavunkel B, Xu YJ, Goyal B et al. Pyrimidine-based inhibitors of CaMKIIδ. Bioorg. Med. Chem. Lett. 18(7), 2404–2408 (2008).
   PubMed Web of Science ®Google Scholar
• Liu Q, Molkentin JD. Protein kinase Cα as a heart failure therapeutic target. J. Mol. Cell. Cardiol. 51(4), 474–478 (2011).
   PubMed Web of Science ®Google Scholar
• Walker JW. Protein kinase C, troponin I and heart failure: overexpressed, hyperphosphorylated and underappreciated? J. Mol. Cell. Cardiol. 40(4), 446–450 (2006).
   PubMed Web of Science ®Google Scholar
• Niizuma S, Inuzuka Y, Okuda J et al. Effect of persistent activation of phosphoinositide 3-kinase on heart. Life Sci. 90(15–16), 619–628 (2012).
   PubMed Web of Science ®Google Scholar
• Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol. Rev. 90(4), 1507–1546 (2010).
   PubMed Web of Science ®Google Scholar
• Abraham ST, Benscoter HA, Schworer CM, Schworer CM, Singer HA. A role for Ca2+/calmodulin-dependent protein kinase II in the mitogen-activated protein kinase signaling cascade of cultured rat aortic vascular smooth muscle cells. Circ. Res. 81(4), 575–584 (1997).
   PubMed Web of Science ®Google Scholar
• Hidalgo CG, Chung CS, Saripalli C et al. The multifunctional Ca(2+)/calmodulin-dependent protein kinase II delta (CaMKIIdelta) phosphorylates cardiac titin’s spring elements. J. Mol. Cell. Cardiol. 54, 90–97 (2013).
   PubMed Web of Science ®Google Scholar
• Picht E, Desantiago J, Huke S, Kaetzel MA, Dedman JR, Bers DM. CaMKII inhibition targeted to the sarcoplasmic reticulum inhibits frequency dependent acceleration of relaxation and Ca(2+) current facilitation. J. Mol. Cell. Cardiol. 42(1), 196–205 (2007).
   PubMed Web of Science ®Google Scholar
• Swulius MT, Waxham MN. Ca(2+)/calmodulin-dependent protein kinases. Cell. Mol. Life Sci. 65(17), 2637–2657 (2008).
   PubMed Web of Science ®Google Scholar
• Barabutis N, Verin A, Catravas JD. Regulation of pulmonary endothelial barrier function by kinases. Am. J. Physiol. Lung Cell. Mol. Physiol. 311(5), L832 (2016).
   PubMed Web of Science ®Google Scholar
• Mayadevi M, Sherin DR, Keerthi VS, Rajasekharan KN, Omkumar RV. Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. Bioorg. Med. Chem. 20(20), 6040–6047 (2012).
   PubMed Web of Science ®Google Scholar
• Mayadevi M, Sherin DR, Keerthi VS, Rajasekharan KN, Omkumar RV. Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. Bioorg. Med. Chem. 20(20), 6040–6047 (2012).
   PubMed Web of Science ®Google Scholar
• Tokumitsu H, Chijiwa T, Hagiwara M, Mizutani A, Terasawa M, Hidaka H. KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 265(8), 4315–4320 (1990).
   PubMed Web of Science ®Google Scholar
• Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000).
   PubMed Web of Science ®Google Scholar
• Yokokura H, Okada Y, Terada O, Hidaka H. HMN-709, a chlorobenzenesulfonamide derivative, is a new membrane-permeable calmodulin antagonist. Jpn J. Pharmacol. 72(2), 127–135 (1996).
   PubMedGoogle Scholar
• Lu Q, Chen Z, Perumattam J et al. Aryl–indolyl maleimides as inhibitors of CaMKIIδ. Part 3: importance of the indole orientation. Bioorg. Med. Chem. Lett. 18(7), 2399–2403 (2008).
   PubMed Web of Science ®Google Scholar
• Komiya M, Asano S, Koike N et al. Synthesis and structure based optimization of 2-(4-phenoxybenzoyl)-5-hydroxyindole as a novel CaMKII inhibitor. Bioorg. Med. Chem. 20(23), 6840–6847 (2012).
   PubMed Web of Science ®Google Scholar
• Beauverger P, Gegis G, Biscarrat S, Duclos O, Mccort G. (2012). 5-Oxo-5,8-dihydropyridol [2,3-d] pyrimidine derivatives as CAMKII kinase inhibitors for treating cardiovascular disease. US patent, 0277220, 2012-11-01
   Google Scholar
• Shahin R, Taha MO. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads. Bioorg. Med. Chem. 20(1), 377–400 (2012).
   PubMed Web of Science ®Google Scholar
• Shahin R, Taha MO. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads. ( 1464–3391 (Electronic)) (2012).
   Google Scholar
• Erickson JR. Mechanisms of CaMKII activation in the heart. Front. Pharmacol. 5, 59 (2014).
   PubMed Web of Science ®Google Scholar
• Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem. Biol. 12(6), 621–637 (2005).
   PubMed Web of Science ®Google Scholar
• Wu P, Clausen MH, Nielsen TE. Allosteric small-molecule kinase inhibitors. Pharmacol. Ther. 156, 59–68 (2015).
   PubMed Web of Science ®Google Scholar
• Oh KS, Oh BK, Park CH et al. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865). Eur. J. Pharmacol. 702(1–3), 218–226 (2013).
   PubMed Web of Science ®Google Scholar
• Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am. J. Phsyiol. Cell Physiol. 290(3), C661–C668 (2006).
   PubMed Web of Science ®Google Scholar
• Schroter T, Minond D, Weiser A et al. Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II). J. Biomol. Screen. 13(1), 17–28 (2008).
   PubMed Web of Science ®Google Scholar
• Feng Y, Yin Y, Weiser A et al. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J. Med. Chem. 51(21), 6642–6645 (2008).
   PubMed Web of Science ®Google Scholar
• Ono-Saito N, Niki I, Hidaka H. H-series protein kinase inhibitors and potential clinical applications. Pharmacol. Ther. 82, 123 (1999).
   PubMed Web of Science ®Google Scholar
• Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a rho-associated protein kinase in hypertension. Nature 389, 990 (1997).
   PubMed Web of Science ®Google Scholar
• Feng Y, Lograsso PV, Defert O, Li R. Rho kinase (ROCK) inhibitors and their therapeutic potential. J. Med. Chem. 59(6), 2269–2300 (2016).
   PubMed Web of Science ®Google Scholar
• Cerebral Vasospasm. Seiler RW, Steiger HJ ( Eds). Springer-Verlag Wien, Vienna, Austria (2001).
   Google Scholar
• Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 4(5), 387–398 (2005).
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Ripasudil: first global approval. Drugs 74, 2211 (2014).
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T et al. Phase II randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am. J. Ophthalmol. 156, 731 (2013).
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T et al. Phase II clinical trials of a selective rho kinase inhibitor, K-115. JAMA Ophthalmol. 131, 1288 (2013).
   PubMed Web of Science ®Google Scholar
• Ikenoya M, Hidaka H, Hosoya T, Suzuki M, Yamamoto N, Sasaki Y. Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific rho-kinase inhibitor. J. Neurochem. 81, 9 (2002).
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Suzuki M, Hidaka H. The novel and specific rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for rho-kinase-involved pathway. Pharmacol. Ther. 93, 225 (2002).
   PubMed Web of Science ®Google Scholar
• Lavogina D, Kalind K, Bredihhina J et al. Conjugates of 5-isoquinolinesulfonylamides and oligo-D-arginine possess high affinity and selectivity towards Rho kinase (ROCK). Bioorg. Med. Chem. Lett. 22(10), 3425–3430 (2012).
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Uehata M, Tamechika I et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57, 976 (2000).
   PubMed Web of Science ®Google Scholar
• Tokushige H, Waki M, Takayama Y, Tanihara H. Effects of Y-39983, a selective rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr. Eye Res. 36, 964 (2011).
   PubMed Web of Science ®Google Scholar
• Feng Y, Cameron MD, Frackowiak B et al. Structure–activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. Bioorg. Med. Chem. Lett. 17, 2355 (2007).
   PubMed Web of Science ®Google Scholar
• Feng Y, Yin Y, Weiser A et al. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective rho kinase (ROCK-II) inhibitors. J. Med. Chem. 51, 6642 (2008).
   PubMed Web of Science ®Google Scholar
• Fang X, Yin Y, Wang B et al. Tetrahydroisoquinoline derivatives as potent and selective rho kinase inhibitors. J. Med. Chem. 53, 5727 (2010).
   PubMed Web of Science ®Google Scholar
• Mimi L, Quan Z, Wang C. Tricyclic pyrido-carboxamide derivatives as rock inhibitors WO 2015002926 A1 (2015).
   Google Scholar
• Mishra RK, Alokam R, Singhal SM et al. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation. J. Chem. Inf. Model. 54(1), 2876–2886 (2014).
   PubMedGoogle Scholar
• Oh KS, Oh BK, Park CH et al. Cardiovascular effects of a novel selective rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865). Eur. J. Pharmacol. 702, 218 (2013).
   PubMed Web of Science ®Google Scholar
• Shahin R, Alqtaishat S, Taha MO. Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors. J. Comput. Aided Mol. Des. 26(2), 249–266 (2012).
   PubMed Web of Science ®Google Scholar
• Feng Y, Lograsso P. Rho kinase inhibitors: a patent review (2012–2013). Expert Opin. Ther. Pat. 24, 295 (2014).
   PubMed Web of Science ®Google Scholar
• Feng Y, Lograsso PV, Defert O, Li R. Rho kinase (ROCK) inhibitors and their therapeutic potential. J. Med. Chem. 59(6), 2269–2300 (2016).
   PubMed Web of Science ®Google Scholar
• Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D. PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu. Rev. Pharmacol. Toxicol. 48, 569–599 (2008).
   PubMed Web of Science ®Google Scholar
• Koide Y. Differential induction of protein kinase C isoforms at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salt-sensitive rats. Hypertens. Res. 26, 421–426 (2003).
   PubMed Web of Science ®Google Scholar
• Liu Q, Molkentin JD. Protein kinase Cα as a heart failure therapeutic target. J. Mol. Cell. Cardiol. 51, 474–478 (2011).
   PubMed Web of Science ®Google Scholar
• Mochly-Rosen D. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKC[epsiv] translocation. Circ. Res. 86, 1173–1179 (2000).
   PubMed Web of Science ®Google Scholar
• Ferreira JC. Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy. J. Mol. Cell. Cardiol. 51, 980–987 (2011).
   PubMed Web of Science ®Google Scholar
• Ferreira JC, Boer BN, Grinberg M, Brum PC, Mochly-Rosen D. Protein quality control disruption by PKCβII in heart failure; rescue by the selective PKCβII inhibitor, βIIV5–3. PLoS ONE 7, e33175 (2012).
   PubMed Web of Science ®Google Scholar
• Ferreira JC, Brum PC, Mochly-Rosen D. βIIPKC and ∊PKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J. Mol. Cell. Cardiol. 51, 479–484 (2011).
   PubMed Web of Science ®Google Scholar
• Omura S, Iwai Y, Hirano A et al. A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J. Antiobiot. (Tokyo) 30(4), 275–282 (1977).
   PubMed Web of Science ®Google Scholar
• Radhika P, Kumar MMK, Nagasree KP. Protein kinase inhibitors from microorganisms. In: Studies in Natural Products Chemistry. Rahman AUr ( Ed.). Elsevier, Amsterdam, The Netherlands 403–445 (2015).
   Google Scholar
• Koshino H, Osada H, Isono K. A new inhibitor of protein kinase C, RK-1409 (7-oxostaurosporine). II. Fermentation, isolation, physico-chemical properties and structure. J. Antiobiot. (Tokyo) 45(2), 195–198 (1992).
   PubMed Web of Science ®Google Scholar
• Osada H, Koshino H, Kudo T, Onose R, Isono K. A new inhibitor of protein kinase C, RK-1409 (7-oxostaurosporine). I. Taxonomy and biological activity. J. Antiobiot. (Tokyo) 45(2), 189–194 (1992).
   PubMed Web of Science ®Google Scholar
• Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159(2), 548–553 (1989).
   PubMed Web of Science ®Google Scholar
• Wagner J, Von Matt P, Sedrani R et al. Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J. Med. Chem. 52(20), 6193–6196 (2009).
   PubMed Web of Science ®Google Scholar
• Van Eis MJ, Evenou JP, Floersheim P et al. 2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes. Bioorg. Med. Chem. Lett. 21(24), 7367–7372 (2011).
   PubMed Web of Science ®Google Scholar
• Li H, Hong Y, Nukui S et al. Identification of novel pyrrolopyrazoles as protein kinase C beta II inhibitors. Bioorg. Med. Chem. Lett. 21(1), 584–587 (2011).
   PubMed Web of Science ®Google Scholar
• Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat. Rev. Drug Discov. 11(12), 937–957 (2012).
   PubMed Web of Science ®Google Scholar
• Packer M. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. J. Am. Coll. Cardiol. 22, 65–72 (1993).
   PubMed Web of Science ®Google Scholar
• Ruboxistaurin: LY 333531. Drugs R D 8(3), 193–199 (2007).
   PubMedGoogle Scholar
• Poli A, Mongiorgi S, Cocco L, Follo MY. Protein kinase C involvement in cell cycle modulation. Biochem. Soc. Trans. 42(5), 1471 (2014).
   PubMed Web of Science ®Google Scholar
• Li H. Protein kinase C: novel isozyme-selective peptide inhibitors. Exp. Opin. Therap. Pat. 16(8), 1183–1187 (2006).
   PubMed Web of Science ®Google Scholar
• Alam MA, Uddin SJ, Brown L. Mitogen-activated protein kinase and natural phenolic compounds in cardiovascular remodeling. In: Studies in Natural Products Chemistry. Rahman AUr ( Ed.), Elsevier, 159–190 (2012).
   Google Scholar
• Goetze S, Xi XP, Kawano Y et al. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 33(1 Pt 2), 183–189 (1999).
   PubMed Web of Science ®Google Scholar
• Willette RN, Eybye ME, Olzinski AR et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J. Pharmacol. Exp. Ther. 330(3), 964 (2009).
   PubMed Web of Science ®Google Scholar
• Ren J, Zhang S, Kovacs A, Wang Y, Muslin AJ. Role of p38 alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J. Mol. Cell. Cardiol. 38(4), 617–623 (2005).
   PubMed Web of Science ®Google Scholar
• Chen C, Yu R, Owuor ED, Kong AN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch. Pharm. Res. 23(6), 605–612 (2000).
   PubMed Web of Science ®Google Scholar
• Cuenda A, Rouse J, Doza YN et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364(2), 229–233 (1995).
   PubMed Web of Science ®Google Scholar
• Jackson JR, Bolognese B, Hillegass L et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 284(2), 687–692 (1998).
   PubMed Web of Science ®Google Scholar
• Wadsworth SA, Cavender DE, Beers SA et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. 291(2), 680–687 (1998).
   Web of Science ®Google Scholar
• Clinical Trials Database: NCT00996840 (2015). https://clinicaltrials.gov/ct2/show/NCT00996840
   Google Scholar
• Laufer SA, Wagner GK, Kotschenreuther DA, Albrecht W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J. Med. Chem. 46(15), 3230–3244 (2003).
   PubMed Web of Science ®Google Scholar
• Das J, Moquin RV, Pitt S et al. Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38α inhibitors. Bioorg. Med. Chem. Lett. 18(8), 2652–2657 (2008).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT00570752 (2015). https://clinicaltrials.gov/ct2/show/NCT00570752
   Google Scholar
• Clinical Trials Database: NCT00399906 (2015). https://clinicaltrials.gov/ct2/show/NCT00399906
   Google Scholar
• Collis AJ, Foster ML, Halley F et al. RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. Bioorg. Med. Chem. Lett. 11(5), 693–696 (2001)
   PubMed Web of Science ®Google Scholar
• Haddad JJ. VX-745. Vertex Pharmaceuticals. Curr. Opin. Investig. Drugs 2(8), 1070–1076 (2001).
   PubMedGoogle Scholar
• Sokol L, Cripe L, Kantarjian H et al. Randomized, dose-escalation study of the p38 alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia 27(4), 977–980 (2013).
   PubMed Web of Science ®Google Scholar
• Skurk C, Maatz H, Rocnik E, Bialik A, Force T, Walsh K. Glycogen-synthase kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ. Res. 96(3), 308–318 (2005).
   PubMed Web of Science ®Google Scholar
• Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3beta in cardioprotection. Circ. Res. 104(11), 1240–1252 (2009).
   PubMed Web of Science ®Google Scholar
• Meijer L, Thunnissen AM, White AW et al. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7(1), 51–63 (2000).
   PubMedGoogle Scholar
• Leclerc S, Garnier M, Hoessel R et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276(1), 251–260 (2001).
   PubMed Web of Science ®Google Scholar
• Leost M, Schultz C, Link A et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267(19), 5983–5994 (2000)
   PubMedGoogle Scholar
• Mettey Y, Gompel M, Thomas V et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 46(2), 22–236 (2003).
   Web of Science ®Google Scholar
• Zhang HC, White KB, Ye H et al. Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg Med. Chem. Lett. 13(18), 3049–3053 (2003).
   PubMed Web of Science ®Google Scholar
• Duan Q, Madan ND, Wu J et al. Role of phosphoinositide 3-kinase IA (PI3K-IA) activation in cardioprotection induced by ouabain preconditioning. J. Mol. Cell. Cardiol. 80, 114–125 (2015).
   PubMed Web of Science ®Google Scholar
• Pretorius L, Du XJ, Woodcock EA et al. Reduced phosphoinositide 3-kinase (p110 alpha) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 175(3), 998–1009 (2001).
   Google Scholar
• Mcmullen JR, Amirahmadi F, Woodcock EA et al. Protective effects of exercise and phosphoinositide 3-kinase(p110 alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 104(2), 612–617 (2007).
   PubMed Web of Science ®Google Scholar
• Jasiński M, Jasińska L, Ogrodowczyk M. Resveratrol in prostate diseases – a short review. Central European J. Urol. 66(2), 144–149 (2013).
   PubMedGoogle Scholar
• Chong E, Chang SL, Hsiao YW et al. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation.. Heart Rhythm. 12(5), 1046–1056 (2015).
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer. Nat. Rev. Drug Discov. 8(8), 627–644 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang J, Fan G, Zhao H et al. Targeted inhibition of focal adhesion kinase attenuates cardiac fibrosis and preserves heart function in adverse cardiac remodeling. Sci. Rep. 7, 43146 (2017).
   PubMed Web of Science ®Google Scholar
• Fang Y, Wang D, Xu X et al. Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor. Eur. J. Med. Chem. 127, 493–508 (2017).
   PubMed Web of Science ®Google Scholar